GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2009

Kemin Picks Up Amalyte Pharmaceuticals

  • Kemin has acquired Amalyte Pharmaceuticals to expand its pharmaceuticals capabilities in inflammatory and immune disease. It will operate as a separate wholly owned subsidiary.

    Kemin, which was founded in 1961 to provide solutions for the agricultural and food industries, has been involved in drug development since 2004. Its pipeline is focused antibacterial, antiviral, and antiinflammatory compounds. Furthest along is Phase IIb Bacillus subtilis PB6, a bacterium against C. difficile associated diarrhea and other acute and chronic gastrointestinal diseases.

    It’s other clinical candidates include a Phase II hepatitis C candidate, Phase II stomach ulcer treatment, and Phase I compounds for asthma, arthritis, and irritable bowel disorder.

    Amalyte will add therapies for ulcerative colitis and allergic rhinitis, both in mid-stage trials. The company’s discovery programs reportedly focus on pulmonary and gastrointestinal indications.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »